The company Astrazeneca has notified that they have withdrawn their MA application in Europe for cediranib. Consequently, NICE will suspend the appraisal. The discussion of this appraisal at the committee meeting on the date above has been cancelled.
 
Status Suspended
Process STA pre-2018
ID number 790

Project Team

Project lead Liv Gualda

Email enquiries

Evidence Review Group / Assessment Group BMJ Evidence Centre, BMJ Group

Timeline

Key events during the development of the guidance:

Date Update
05 October 2016 The Appraisal Committee was due to meet on 15 November 2016 to discuss cediranib for treating relapsed, platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer. The company has notified that they have withdrawn their MA application in Europe for cediranib. Consequently, NICE will suspend the appraisal. The discussion of this appraisal at the committee meeting on the date above has been cancelled.
21 September 2016 Suspended, The company Astrazeneca has notified that they have withdrawn their MA application in Europe for cediranib. Consequently, NICE will suspend the appraisal. The discussion of this appraisal at the committee meeting on the date above has been cancelled.
24 June 2016 Invitation to participate
27 November 2015 Draft scope documents
04 November 2015 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance